Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration.
Dallob A, De Lepeleire I, Van Hecken A, Porras A, Depré M, Mukhopadhyay S, Flynn M, Wildonger L, Gottesdiener K, Tanaka W, De Schepper P.
Dallob A, et al. Among authors: de schepper p, de lepeleire i.
Inflamm Res. 1999 Dec;48 Suppl 2:S130-1. doi: 10.1007/s000110050552.
Inflamm Res. 1999.
PMID: 10667849
Clinical Trial.
No abstract available.